CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSKAccesswire • 05/08/23
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business UpdateAccesswire • 04/25/23
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023Accesswire • 04/18/23
CureVac Announces Closing of $250 million Follow-on Public Offering of Common SharesAccesswire • 02/10/23
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development ProgramsAccesswire • 01/30/23
Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government's pandemic responseMarket Watch • 01/09/23
CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu VaccinesInvestorPlace • 01/06/23
CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development ProgramsAccesswire • 01/06/23
CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive ProgramAccesswire • 12/14/22
Wall Street Analysts Believe CureVac N.V. (CVAC) Could Rally 139%: Here's is How to TradeZacks Investment Research • 11/22/22
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business UpdateAccesswire • 11/16/22
CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102Accesswire • 11/11/22